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Abstract: Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
characterized by progressive involuntary movements, neuropsychiatric disturbances, and 
cognitive impairment. The use of tetrabenazine (TBZ), a specific inhibitor of vesicular 
monoamine transporter, is approved for chorea in HD patients. We aimed to review the medi-
cal literature concerning the efficacy and tolerability of TBZ in the treatment of HD patients 
and to report our personal experience about TBZ use in a cohort of HD patients. We searched 
PubMed (1960 to July 2010) using the following keywords: ‘‘tetrabenazine’’ + ‘‘huntington’s 
disease + chorea”. We included randomized controlled trials, open-label trials, and retrospective 
studies. We excluded case reports and studies conducted on fewer than 20 patients. In addi-
tion, we retrospectively evaluated 2 years’ follow-up of TBZ treatment on motor and cognitive 
performances and functional abilities in 28 HD patients,   compared with 10 patients treated 
by other neuroleptics (clotiapine). Only four papers fulfilled the requested criteria. In the first 
study, which included 84 randomized outpatients, TBZ showed a significant improvement of 
chorea compared with placebo. In the open-label study extension, TBZ confirmed its efficacy on 
chorea, with a frequent occurrence of withdrawals due to side effects. In a retrospective study of 
long-term efficacy, 63 patients under TBZ therapy for an average period of 34 months showed 
a stable effect on chorea, despite a slight reduction of effect over time. In a telephone survey 
conducted on a total of 118 patients affected by different movement disorders, TBZ showed 
the most favorable effect for the 28 included HD patients. Our HD patients showed a slight 
deterioration of motor performances over time that was nonsignificant compared with TBZ or 
clotiapine treatments. Despite the fact that the global effect of TBZ seems positive in HD, more 
attention on evaluating symptomatic treatments for cognitive and psychiatric deterioration as 
well as motor deterioration would alleviate this devastating disorder until a neuroprotective 
treatment becomes available.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
characterized by midlife onset and a triad of symptoms, including progressive 
involuntary movements, neuropsychiatric disturbances, and cognitive impairment.1 
HD is caused by an enlarged CAG repeat expansion in the huntingtin protein gene 
on the short arm of chromosome 4, which results in a diffuse neuronal degeneration 
preferentially involving striatum and cortex.2 As the disease progresses, motor disability 
develops, especially stereotypic involuntary movements (Huntington’s chorea). There 
is no provided treatment for delaying the development of the disease or to stop the 
progression of HD. The current management of HD is focused on symptom reduction, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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because there is no treatment able to avoid the progressive 
global deterioration and death occurring within 10–20 years 
of disease onset. The goals of managing HD are to reduce 
the impact of the disease on individuals’ abilities, primarily 
improving motor function, in order to obtain a favorable 
impact on their quality of life.
Movement disorders in HD consist of involuntary 
movements (chorea and dystonia) and impairment of voluntary 
movements (eg, gait, speech, swallowing, fine motor tasks). 
Both chorea and impairment of voluntary movements progress 
in the middle stages of HD, whereas in the progression of the 
disease, chorea often decline as patients become rigid and 
unable to initiate voluntary movements. Some medications 
that are effective on chorea may worsen voluntary movement, 
compromising gait or swallowing, and may induce depres-
sion, sedation, and tardive dyskinesia. Many pharmacological 
interventions have been reported in HD for their efficacy in 
the treatment of movement disorders such as hyperkinesias, 
dystonia, myoclonus, and tics. Among them, neuroleptics have 
demonstrated effectiveness in the treatment of chorea but may 
induce side effects on motor performance.3,4
Tetrabenazine (TBZ; Ro 1-9569) was first synthesized in 
1956, and in 1958 was approved for the treatment of neuroses 
and psychoses/schizophrenia in Finland, the Netherlands, 
Switzerland, and the UK. Since the 1980s, TBZ has been used 
in the treatment of different dyskinesias. In May 2008, it was 
approved by the US Food and Drug Administration for the treat-
ment of chorea in HD. To date, TBZ is marketed with the same 
indication in many other countries.5 TBZ exerts its antichoreic 
effects by reducing the amount of dopamine in the brain in two 
ways.6 The first and more widely recognized way is by prevent-
ing dopamine release from vesicles, inhibiting the uptake of 
monoamines. Special proteins called vesicular monoamine 
transporters (VMATs) are responsible for neurotransmitter 
transport into the vesicles. TBZ binds to the VMATs, preventing 
them from performing this function. As such, neurotransmitters 
like dopamine are not stored in vesicles and cannot be released 
into the synapse. The highest binding density for TBZ is in 
the caudate nucleus, putamen, and nucleus accumbens, areas 
known to bear the brunt of pathology in HD.7,8
In addition, TBZ reduces dopamine by blocking dop-
amine receptors, as has been shown in in vitro studies.9,10 
TBZ binds to receptors on the surface of the receiving nerve 
cell, blocking dopamine from passing on its message. The 
mechanism of inhibiting dopamine receptors, however, is 
thought to be less significant at the TBZ dosages used in HD 
patients, although it may possibly be responsible for acute 
dystonic reactions, which are rarely reported with TBZ.11
Table 1 Main data across the selected studies about TBZ in HD patients
Study Year Study design No. of HD patients  
under TBZ
No. of HD  
patients on  
placebo
No. of  
follow-up
Maximum time  
of observation
Mean TBZ  
dosage
Short-term  
change of TMC
Long-term  
change of TMC
Clinical global  
impression  
of change
Adverse effects Serious adverse  
accidents or causes  
of withdrawal
Paleacu et al18 2004 Open-label long-term  
follow-up
28 (HD plus other types  
of chorea) among a total of  
150 patients with different  
movement disorders
88 weeks Up to 150 mg/die  
(76.2 ± 38.4 mg,  
range 25–175)
32.14% marked 
improvement  
(among the total  
chorea patients)
Not defined in  
HD patients
worsening (3), lack of 
benefit (7 patients with 
chorea including HD)
Huntington  
Study Group15
2006 Multicenter, prospective,  
double-blind,  
placebo-controlled,  
dose-finding
54 30 1 12 weeks Up to 100 mg/die  
(range 25–100)
−5 ± 0.5 (M ± Se)  
(P = 0.0001  
vs placebo)
40% much  
improved  
(P = 0.0007  
vs placebo)
Sedation (13),  
akatisia (4),  
parkinsonism, (2),  
depression (5)
Suicide (1), intracerebral 
hemorrhage consequent to 
a fall (1), breast cancer (1)
Fasano et al17 2008 Long-term  
retrospective
68 0 2 137.6 + 100 weeks 57.5 ± 14.7 mg  
(range 6.25–150)
−21% (0–20)  
(P = 0.00001  
vs baseline)
−9% (1–22)  
(n.s. vs baseline)
Drowsiness (17),  
depression (11),  
disturbances of  
gut function (8),  
worsening of  
parkinsonism (4), 
xerostomia (2),  
hypotension (1)
worsening of psychiatric 
disturbance (1), disabling 
asthenia (1)
Frank16 2009 Open-label  
extension study
45 0 3 80 weeks Up to 200 mg/die  
(range 12.5–175 mg)
−5.8 ± 5 (M + SD)  
(P , 0.05  
vs baseline)
−4.6 ± 5.5 (M + SD)  
(P , 0.05  
vs baseline)
Sedation (18),  
depressed mood (17), 
anxiety (13),  
insomnia (10),  
fatigue (7), agitation (5),  
fall (4), dysphagia (3),  
dystonia (3)
vocal tics, depression, 
delusions (3); methastatic 
breast cancer (1); elevated 
bilirubine level, akatisia (1); 
elevated liver enzyme (1)
Abbreviations: HD, Huntington’s disease; TBZ, tetrabenazine; TMC, Total Maximal Chorea score.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Our aim was to review the medical literature concerning 
the efficacy and tolerability of TBZ in the treatment of chorea 
in HD patients. In addition, we aimed to report our personal 
experience about TBZ use in a cohort of HD patients.
Materials and methods
We searched PubMed (1960 to July 2010) using the   following 
keywords: ‘‘tetrabenazine’’ + ‘‘huntington’s disease + 
  chorea”. We included randomized controlled trials, open-
label trials, and retrospective studies. We excluded case 
reports and studies conducted on fewer than 20 patients.
In addition, we retrospectively evaluated 2 years’ follow-up 
of TBZ treatment on motor and cognitive performances and 
functional abilities in 28 HD patients, compared with 10 
patients treated with other neuroleptics (clotiapine).12
The clinical outcome of 44 genetically confirmed HD 
patients, seen for the first time at the Center for   Huntington’s Dis-
ease of the Neurological and Psychiatric Sciences Department 
of Bari Aldo Moro University, Bari, Italy, and assigned to TBZ 
or clotiapine treatment, was checked after 24–30 months’ (mean 
25.5 ± 2.3 months) observation.   Subjects were titrated to the 
more efficacious and well-  tolerated individual dose for both 
treatments, with a maximum of 200 mg/day for TBZ and 100 mg 
for clotiapine. All subjects had been assessed according to the 
motor section of Unified Huntington’s Disease Rating Scale 
(UHDRS)13 and the Total Functional Capacity Scale14 at the 
first access and after 24–30 months of treatment. The statistical 
  analysis included two-way analysis of variance (ANOVA) with 
clinical scores as variables and time of observation and treat-
ments as factors. In addition, in order to assess the efficacy of 
TBZ and clotiapine according to severity of motor disability, 
we evaluated the correlation between the total maximal chorea 
score in basal condition and the change occurring after treatment, 
employing Spearman’s correlation test.
Results
Among the reviewed papers, only three fulfilled all the requested 
criteria, and one reported results from 28 patients affected by 
chorea, including an undefined number of HD sufferers.
The Huntington Study Group demonstrated the efficacy 
of TBZ in the first multicenter, prospective, double-blind, 
placebo-controlled, dose-finding study of TBZ for the treat-
ment of chorea in HD.15 Eighty-four ambulatory patients were 
randomized (in a 2:1 ratio) to receive either placebo or TBZ for 
12 weeks. TBZ was increased over 7 weeks up to a maximum 
of 100 mg/day or until the desired antichoreic effect occurred 
or intolerable adverse effects supervened. Primary outcome 
measure was the reduction of 5.0 units from baseline in the 
chorea score of the UHDRS in TBZ-treated patients, compared 
with a reduction of 1.5 units on placebo treatment (Table 1).15
Table 1 Main data across the selected studies about TBZ in HD patients
Study Year Study design No. of HD patients  
under TBZ
No. of HD  
patients on  
placebo
No. of  
follow-up
Maximum time  
of observation
Mean TBZ  
dosage
Short-term  
change of TMC
Long-term  
change of TMC
Clinical global  
impression  
of change
Adverse effects Serious adverse  
accidents or causes  
of withdrawal
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follow-up
28 (HD plus other types  
of chorea) among a total of  
150 patients with different  
movement disorders
88 weeks Up to 150 mg/die  
(76.2 ± 38.4 mg,  
range 25–175)
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improvement  
(among the total  
chorea patients)
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HD patients
worsening (3), lack of 
benefit (7 patients with 
chorea including HD)
Huntington  
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double-blind,  
placebo-controlled,  
dose-finding
54 30 1 12 weeks Up to 100 mg/die  
(range 25–100)
−5 ± 0.5 (M ± Se)  
(P = 0.0001  
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40% much  
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(P = 0.0007  
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Sedation (13),  
akatisia (4),  
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depression (5)
Suicide (1), intracerebral 
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(range 6.25–150)
−21% (0–20)  
(P = 0.00001  
vs baseline)
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(n.s. vs baseline)
Drowsiness (17),  
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disturbances of  
gut function (8),  
worsening of  
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xerostomia (2),  
hypotension (1)
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(range 12.5–175 mg)
−5.8 ± 5 (M + SD)  
(P , 0.05  
vs baseline)
−4.6 ± 5.5 (M + SD)  
(P , 0.05  
vs baseline)
Sedation (18),  
depressed mood (17), 
anxiety (13),  
insomnia (10),  
fatigue (7), agitation (5),  
fall (4), dysphagia (3),  
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vocal tics, depression, 
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The same group of study participants was given the 
opportunity to participate in an open-label extension study. 
Subjects who completed the 13-week, double-blind protocol 
were invited to participate in this open-label extension study 
for up to 80 weeks.16 Of the 75 participants, 45   subjects 
  completed 80 additional weeks of treatment with TBZ. Sub-
jects were titrated to the best individual dose or a   maximum 
of 200 mg/day. Chorea were assessed using the Total Maximal 
Chorea (TMC) score from the Unified Huntington Disease 
Rating Scale.13 At week 80, chorea had significantly improved 
ANOVA:
time of observation: F 3.68 Df 1 p 0.058
treatment x time of observation: F 0.026 Df 1 p 0.6
ANOVA:
time of observation: F 1.18 Df 1 p 0.19
treatment x time of observation: F 0.1 Df 1 p 0.7
ANOVA:
time of observation: F 0.73 Df 1 p 0.39
treatment x time of observation: F 0.25 Df 1 p 006
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Figure 1 Mean values and standard deviations of A) the global motor score of the Unified Huntington’s Disease Rating Scale (UHDRSM), B) the chorea score, and 
C) the Total Functional Capacity (TFC) Scale in a cohort of Huntington’s disease patients before and after 2 years of treatment. The results of two-way analysis of variance 
(ANOvA) are reported.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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from baseline with a mean reduction in the TMC score of 4.6 
(standard deviation 5.5) units. The mean dose at week 80 was 
63.4 mg (range 12.5–175 mg). Three participants terminated 
due to adverse events. The other 26 subjects chose not to 
continue study extension for various reasons (Table 1).
Fasano et al17 performed a retrospective study to evaluate 
the long-term efficacy and safety of TBZ in managing chorea. 
In the study, 68 HD patients were analyzed. Patients were 
treated with TBZ for a mean period of 34.4 ± 25.2 months. 
At the first follow-up, 9.7 ± 7.8 months after the prescription 
of TBZ (mean dose 35.3 ± 14.7 mg), mean score of chorea 
was 8.2 ± 4.1 (−21% compared with baseline), whereas at 
the latest follow-up visit (mean dose 57.5 ± 14.7 mg), it was 
9.5 ± 5.0 (9%). During the follow-up, the clinical benefit per-
sisted, but the magnitude was reduced despite a progressive 
increase of the doses (up to 60%). Five patients (7%) did not 
gain any improvement, and TBZ was discontinued. There 
were two withdrawals because of side effects; 34 patients 
reported at least one side effect (Table 1).
The authors reported that TBZ was well tolerated and 
produced long-term improvement of motor symptoms in 
HD patients, although a slight reduction of benefit occurred 
during the course of treatment.17
Paleacu et al18 studied a total of 118 patients with hyper-
kinetic movement disorders, including a group of 28 subjects 
with chorea, with an unpredictable number of HD sufferers. 
Patients were assessed in the follow-up visit or by direct and 
telephone interview using the Clinical Global Impression of 
Change (CGIC), and the overall efficacy of treatment was 
shown via a composite score made up from the patient’s and 
the caregiver’s score.18 Significant improvement of hyper-
kinesias was seen in 61% of patients, with a subgroup of 
subjects with chorea (nine, including an undefined   number 
of HD patients) and facial dyskinesias responding most 
favorably (Table 1).18
Our experience
Among 44 patients, 32 had been assigned to TBZ and 12 to 
clotiapine treatment. Four patients in the TBZ group and two in 
the clotiapine group were lost to the 2-year follow-up (two 
patients were hospitalized, two changed address, and two fur-
ther patients discontinued TBZ after 2 months’ therapy because 
of the sedation side effect). The remainder of the patients took 
the assigned treatment during the observation period, though in 
10 patients in the TBZ group and five in the clotiapine group 
the minimum efficacious dosage was further reduced because 
of the occurrence of side effects (sedation, depression, and 
confusion in both groups), which were relatively resolved at 
the 2-year follow-up (two patients in the TBZ group and one 
in the clotiapine group reported sedation; two patients on TBZ 
reported fatigue). As a consequence, the TBZ dose was, on 
average, 75 ± 15 mg and the clotiapine dose was 30 ± 5.5 mg. 
The motor performances worsend in a nonsignificant way in 
both groups, without significant differences between the two 
treatments (Table 1; Figure 1A). In particular, in the TBZ 
group, the progression of chorea seemed slightly reduced com-
pared with the clotiapine group (Table 1; Figure 1B). In fact, 
the mean change of chorea score over time was +0.85 ± 2.5 in 
the TBZ group and +2.3 ± 4.5 in the clotiapine group (t-test: 
nonsignificant). The functional capacities remained stable at 
follow-up in the TBZ group, with a slight deterioration in the 
clotiapine group (Table 1; Figure 1C).
The change of chorea score correlated in a negative 
way with the basal values in the TBZ group (Spearman’s 
correlation test in the TBZ group: 0.521, P = 0.002; in the 
clotiapine group: 0.564, nonsignificant), suggesting more 
effect in patients with severe hyperkinesias.
Conclusion
Few studies have evaluated the efficacy of TBZ in large 
samples of HD patients, though it is the only approved drug 
for HD. In general, the symptomatic treatment of HD has 
not been evaluated in large cohorts of patients, and there 
are many aspects of the disease, such as other abnormal 
involuntary movements, cognition, affective disorders, and 
behavioral disturbances, for which the best therapeutic 
strategies are not determined.19,20 Only one study15 reported 
results of a short-term, double-blind, placebo-randomized 
design, and only one prospective16 and one retrospective17 
study on the long-term effect of TBZ are available. A study 
Table 2 Mean values and standard deviations of the principal clinical features in our HD patients
Tetrabenazine 
N = 28
Clotiapine 
N = 10
Basal 1 year 2 years Basal 1 year 2 years
TFC   5.9 ± 3.9   5.8 ± 2.3   5.5 ± 3.9   7.13 ± 5.4   6.9 ± 4.5   5.7 ± 4.3
UHDRSM 43.77 ± 22 44.5 ± 20 50.21 ± 27 40.26 ± 28 44.3 ± 19.8 55.88 ± 22.3
Chorea    10 ± 5.96   9.6 ± 4.66   10.7 ± 4.29   9.8 ± 5.4   9.9 ± 6.3 12.12 ± 4.2
Abbreviations: HD, Huntingdon’s disease; TFC, Total Functional Capacity Scale; UHDRSM, Motor Section of the Unified Huntington’s Disease Rating Scale.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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by Paleacu et al18 did not explain the exact number of HD 
patients studied. In addition, the comparison between TBZ 
and other classical neuroleptics has not been extensively 
studied in any study. Brusa et al21 compared the effects of 
TBZ with those obtained by   aripiprazole in six HD patients, 
finding a slightly prevalent effect of TBZ on chorea but 
a greater tolerability of aripiprazolo concerning seda-
tion and depression. The overall evaluation of the results 
obtained from the few TBZ   studies on HD seems to partly 
support its efficacy on   choreatic   movements. The poten-
tial adverse effects of TBZ need a careful evaluation and 
dosage a  djustment.22 In fact, TBZ causes several adverse 
events, which in many cases has determined its reduction 
or even withdrawal. The dosage seems to vary conspicu-
ously across studies and in the same patient group, in an 
attempt to   balance efficacy and   tolerability. In   addition, the 
efficacy of TBZ is contrasted with the natural progression 
of the disease and the loss of   efficacy.17 Our observation 
confirms that in long-term studies the balance between 
efficacy and tolerability reduces the potential effect on 
motor symptoms of both TBZ and the considered atypical 
neuroleptic drug. In fact, compared with cases reported in 
previous studies, in our patients, TBZ exhibited a global 
reduction of efficacy concurring with a minor representa-
tion of adverse effects at the 2-year follow-up. Moreover, 
the worsening of chorea was not significant in both groups 
and appeared to be further reduced in TBZ-treated patients. 
The stability of functional capacities across time suggests 
that the medium–low drug dosages may partly reduce the 
progression of chorea without   compromising other abili-
ties or the occurrence of strong depression, sedation, or 
confusion. Animal studies have pointed to an important 
role of the dopaminergic pathway in HD and have sug-
gested that the dopamine signaling pathway constitutes a 
potential therapeutic target for HD treatment.23,24 Recently, 
long-term feeding with TBZ (combined with levodopa) 
  alleviated the motor deficits and reduced the striatal 
  neuronal loss in the mouse model of HD, thus suggesting 
a neuroprotective effect.25 However, our retrospective 
  observation does not exclude a lack of effect of both treat-
ments on illness progression, for the absence of a placebo 
group, and may contribute to   confirming the hypothesis 
suggested by Fasano et al with regard to a long-term loss 
of efficacy.17   Nevertheless, we observed a major effect in 
patients presenting with more severe chorea, indicating an 
efficacy of TBZ in the   progression of motor   deterioration. 
The hypothesis that TBZ may act as a neuroprotective 
rather than a symptomatic drug should be tested in more 
prolonged study designs.25 The overall impression being 
derived from the available data and our personal experi-
ence is that the problems linked with the symptomatic 
treatments need further study in HD, especially when the 
long-term outcome has to be considered, also taking into 
consideration comparison with the efficacy and tolerability 
of typical and atypical neuroleptics frequently used in HD 
patients. Despite the global effect of TBZ seeming positive 
in HD, more   attention on evaluating symptomatic treat-
ments for cognitive and   psychiatric deterioration as well 
as motor deterioration would contribute to alleviating this 
devastating disorder until a protective treatment against 
progressive neurodegeneration becomes available.
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